AN2 Therapeutics, Inc.

Listed Company

ANTXCIK 0001880438NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

—

Total Assets

$61.95M

Equity

$53.06M

Shares Out

36.02M

Op. Cash Flow

$-29.83M

ANTX$4.67+326.03% · past yearDBEQ Basic

Daily closing prices

Business

AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its proprietary boron chemistry platform. The company's pipeline spans hematologic diseases, infectious diseases, and oncology, with lead candidates including epetraborole for polycythemia vera and Mycobacterium abscessus lung disease, and AN2-502998 for Chagas disease. AN2 operates through licensed intellectual property, relies on third-party contract manufacturers for all drug production, and funds certain development programs through non-dilutive grant agreements.

Summary from 10-K filed 2026-03-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	25	40	55	29	16
General and administrative	13	14	15	13	5
Restructuring charges	—	2	—	—	—
Total operating expenses	38	57	70	42	22
Loss from operations	−38	−57	−70	−42	−22
Interest income	3	5	5	—	—
Other income	1,000	1,000	43,000	1	−38,000
Net loss attributable to common stockholders	−35	−51	−65	−43	−28
Net loss per share attributable to common stockholders, basic	−1.16	−1.72	−2.74	−2.79	−10.64
Net loss per share attributable to common stockholders, diluted	−1.16	−1.72	−2.74	−2.79	−10.64
Weighted-average number of shares used in computing net loss per share, basic	30	30	24	15	3
Weighted-average number of shares used in computing net loss per share, diluted	30	30	24	15	3
Unrealized gain (loss) on investments	26,000	−244,000	649,000	−347,000	−27,000
Comprehensive loss	−35	−52	−64	−41	−22

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	20	21	16	27	12
Short-term investments	38	62	92	69	46
Prepaid expenses and other current assets	2	3	3	3	2
Total current assets	60	86	111	99	60
Long-term investments	2	5	27	3	3
Other assets, long-term	0	804,000	1	720,000	—
Total assets	62	92	139	103	65
Accounts payable	3	3	3	2	1
Accrued compensation	2	2	4	2	916,000
Accrued liabilities	2	4	7	3	1
Other current liabilities	1	791,000	666,000	—	—
Total current liabilities	9	10	14	7	3
Other non-current liabilities	170,000	0	—	—	—
Total liabilities	9	10	14	7	3
Commitments and contingencies (Note 7)	—	—	—	—	—
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.00001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 27,413,171 and 29,919,634 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	—	—	—	—	—
Additional paid-in capital	294	288	279	185	—
Accumulated other comprehensive gain	57,000	31,000	275,000	−374,000	−27,000
Accumulated deficit	−241	−206	−154	−90	−47
Total stockholders' equity	53	82	125	95	−47
Total liabilities and stockholders' equity	62	92	139	103	65

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net Loss	−35	−51	−65	−41	−22
Stock-based compensation expense	6	8	8	4	974,000
Net accretion of discount on investments	−1	−3	−3	−692,000	53,000
Prepaid expenses and other assets	2	807,000	−1	−2	−1
Accounts payable	−296,000	641,000	553,000	2	417,000
Accrued compensation	742,000	−2	2	1	490,000
Accrued liabilities	−2	−2	4	2	512,000
Other current liabilities	438,000	126,000	666,000	—	—
Other non-current liabilities	170,000	—	—	—	—
Net cash used in operating activities	−30	−49	−53	−33	−20
Purchases of investments	−46	−47	−132	−94	−77
Maturities of investments	75	101	89	72	27
Net cash provided by investing activities	28	55	−43	−22	−50
Proceeds from issuance of common stock under the ESPP	86,000	147,000	366,000	—	—
Proceeds from exercise of stock options	27,000	225,000	99,000	—	11,000
Net cash provided by financing activities	113,000	372,000	85	70	79
Net (decrease) increase in cash and cash equivalents	−1	6	−12	15	8

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AN2 Therapeutics, Inc.'s CIK number?

AN2 Therapeutics, Inc.'s SEC CIK number is 0001880438 (1880438). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AN2 Therapeutics, Inc.'s SEC filings?

All of AN2 Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AN2 Therapeutics, Inc. last report earnings?

AN2 Therapeutics, Inc. (ANTX) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-216752). This is AN2 Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is AN2 Therapeutics, Inc.'s most recent earnings 8-K?

AN2 Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-216752. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AN2 Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →